Myasthenia Gravis Drugs Market Size, Share, Trends, Analysis and Forecasts To 2021
Market Research analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16 % during the period 2017-2021.
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.
Download Sample Report @ https:// marketreportscenter. com / request-sample / 499369
Covered in this report
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.
The market is divided into the following segments based on geography: Americas APAC EMEA
Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors Flamel Technologies F. Hoffmann-La Roche Grifols Pfizer Shire Valeant Pharmaceuticals
Other prominent vendors Alexion Pharmaceuticals Catalyst Pharmaceuticals CSL